Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy.

BACKGROUND & AIMS Photodynamic therapy (PDT) is a technique for nonsurgical treatment of patients with dysplasia in Barrett's esophagus. The primary endpoint for PDT has been resolution of dysplasia. We studied the effect of PDT at the genetic level. METHODS Archival material from 3 patients who had initial improvement in dysplasia after PDT but occurrence of high-grade dysplasia during follow-up was used. Biopsy specimens were analyzed for increased proliferation, aneuploidy, p53 protein overexpression, p53 mutations, and p16 promoter hypermethylation. RESULTS Patients developed high-grade dysplasia 16, 28, and 37 months after PDT. In all cases, one or more genetic markers were positive after PDT treatment, whereas histology was downstaged consistently after therapy. Increasing genetic abnormalities were noted by the end of follow-up. CONCLUSIONS Genetic abnormalities may persist after PDT despite phenotypical improvement of dysplasia. These patients may progress to high-grade dysplasia or develop adenocarcinoma. Histologic improvement in dysplasia is an inadequate endpoint for PDT in patients with Barrett's esophagus.

[1]  P. D. James,et al.  Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus. , 1989, Gut.

[2]  Brian J. Reid,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: Prospective endoscopic surveillance of a cohort , 1992 .

[3]  Carissa A. Sanchez,et al.  Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. , 1996, Oncogene.

[4]  S N Thibodeau,et al.  Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. , 1998, Nucleic acids research.

[5]  M. Pera.  Epidemiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[6]  W. Hop,et al.  Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. , 1995, Cancer research.

[7]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[8]  J. Byrne,et al.  Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. , 1998 .

[9]  G. Viale,et al.  p53 protein accumulation and p53 gene mutation in esophageal carcinoma , 1997, Cancer.

[10]  H. van Dekken,et al.  Detection of genetic changes in Barrett's adenocarcinoma and Barrett's esophagus by DNA in situ hybridization and immunohistochemistry. , 1994, Cytometry.

[11]  C. Hsieh,et al.  Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. , 1998, Gastroenterology.

[12]  I. Salmon,et al.  Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus , 2000, Gut.

[13]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[14]  Carissa A. Sanchez,et al.  Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. , 2000, Journal of the National Cancer Institute.

[15]  Kenneth K Wang,et al.  Current status of photodynamic therapy of Barrett's esophagus. , 1999, Gastrointestinal endoscopy.

[16]  A. Cameron,et al.  Epidemiology of columnar-lined esophagus and adenocarcinoma. , 1997, Gastroenterology clinics of North America.

[17]  B. Reid,et al.  p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.

[18]  J. Roth,et al.  Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.

[19]  R. Sampliner,et al.  Barrett's oesophagus—cancer risk, biology and therapeutic management , 1993 .

[20]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[21]  M. Werner,et al.  Malignant progression in Barrett's esophagus: pathology and molecular biology. , 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[22]  The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: Report on the cleveland clinic barrett's esophagus registry , 1999 .

[23]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. , 1999, Gastrointestinal endoscopy.

[24]  R. Fitzgerald,et al.  Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. , 1999, Gastroenterology.

[25]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Sebo,et al.  Digital image analysis. , 1995, Mayo Clinic proceedings.

[27]  L. Gossner,et al.  Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid , 1998 .

[28]  V. Álvarez,et al.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. , 1997, Journal of clinical pathology.

[29]  G. Tytgat,et al.  The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence. , 1995, Surgical oncology.